# US 2026/0091078 A1 · Oligopeptide that inhibits angiogenesis and vascular function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091078 A1
- Document ID: US20260091078A1
- Status: Published application
- Kind: A1
- Application number: 17/778,396
- Filed: 2020-07-07
- Published: 2026-04-02
- Earliest claimed: 2019-11-20
- Assignees: Jakob TRIEBEL; Thomas Bertsch; Universidad Nacional Autonoma De Mexico
- Applicants: Universidad Nacional Autonoma De Mexico
- Inventors: Jakob TRIEBEL; Thomas Bertsch; Marid del Carmen Clapp Jiminez L.; Juan Pablo Robles Alvarez; Maria Magdalena Zamora Corona; Gonzalo Martinez de la Escalera Lorenzo
- Web page: https://patentgrep.com/patent/US20260091078A1

## CPC

- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An oligopeptide that inhibits angiogenesis and vascular function which oligonucleotide has a length of 3 to 7 amino acids and comprises or consists of the sequence X2-X3-X4, wherein X2 is a basic or amide amino acid, X3 is a small amino acid and X4 is a basic amino acid, charged at neutral pH or the sequence X1-X2-X3-X4, wherein X1 is a polar non-charged amino acid and X2, X3 and X4 are identical to X2, X3 and X4 in X2-X3-X4, or the sequence X1-X2-X3-X4-X5-X6-X7, wherein X1, X2, X3 and X4 are identical to X1, X2, X3 and X4 in X1-X2-X3-X4, X5 is a small amino acid, X6 is a hydrophobic amino acid and X7 is a hydrophobic amino acid.

## Claims

### Claim 1

An oligopeptide that for inhibition of angiogenesis and vascular function which oligopeptide has a length of 3 to 7 amino acids and comprises or consists of
the sequence X2-X3-X4, wherein
X2 is a basic amino acid or an amide amino acid,
X3 is Ala or Gly and
X4 is a basic amino acid, charged at neutral pH
or
the sequence X1-X2-X3-X4, wherein
X1 is a polar non-charged amino acid and
X2, X3 and X4 are identical to X2, X3 and X4 in X2-X3-X4,
or
the sequence X1-X2-X3-X4-X5-X6-X7, wherein
X1, X2, X3 and X4 are identical to X1, X2, X3 and X4 in X1-X2-X3-X4,
X5 is Gly, Ser, or Ala,
X6 is a hydrophobic amino acid and
X7 is a hydrophobic amino acid, wherein
X1 is Thr, Ser, Asn, Glu, Gly, or Ala,
X2 is His, Am, Lys, Gln, or Asn,
X6 is Phe, Ala, Leu, Ile, Trp or Pro and
X7 is Phe, Ala, Leu, Ile, Trp or Pro,
wherein X4 is Lys for use in the treatment or prevention of a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts,
or
wherein X4 is Arg for use in the treatment or prevention of cancer, a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts.

### Claim 2 (depends on 1)

The oligopeptide according to claim 1 for use in the treatment or prevention of cancer, a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts, wherein
X1 is Thr,
X2 is His,
X3 is Gly,
X4 is Arg,
X5 is Gly,
X6 is Phe and
X7 is Ile.

### Claim 3

An oligopeptide for inhibiting angiogenesis and vascular function which oligopeptide has a length of 3 to 7 amino acids and comprises or consists of
the sequence X1-X2-X3, wherein
X1 is an acid amino acid with negative charge at neutral pH,
X2 is a polar amino acid and
X3 is an amino acid with positive charge at neutral pH
or
the sequence X1-X2-X3-X4, wherein
X1, X2 and X3 are identical to X1, X2 and X3 in X1-X2-X3 and
X4 is a polar aromatic amino acid
or
the sequence X1-X2-X3-X4-X5-X6-X7, wherein
X1, X2, X3 and X4 are identical to X1, X2, X3 and X4 in X1-X2-X3-X4,
X5 is a polar amino acid,
X6 is a hydrophobic amino acid and
X7 is a hydrophobic amino acid,
wherein
X1 is Asp or Glu,
X2 is Gln, Asn, Ser or Thr,
X3 is Arg or Lys,
X4 is Tyr,
X5 is Gln, Asn, Ser or Thr,
X6 is Phe, Ala, Leu, Ile, Trp or Pro and
X7 is Phe, Ala, Leu, Ile, Trp or Pro.

### Claim 4 (depends on 3)

The oligopeptide according to claim 3, wherein
X1 is Glu,
X2 is Gln,
X3 is Lys,
X5 is Ser,
X6 is Phe and
X7 is Leu.

### Claim 5

An oligopeptide for inhibiting angiogenesis and vascular function which has a length of 7 amino acids and the sequence X1-X2-X3-X4-X5-X6-X7, wherein
X1 is the amino acid Thr, Asp or Glu,
X2 is the amino acid His or Gln,
X3 is the amino acid Gly or Lys,
X4 is the amino acid Arg if X3 is Gly or the amino acid Tyr if X3 is Lys,
X5 is the amino acid Gly or Ser,
X6 is the amino acid Phe and
X7 is the amino acid Ile or Leu.

### Claim 6 (depends on 1)

The oligopeptide according to claim 1 for use in the treatment or prevention of cancer, a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts which oligopeptide consists of or comprises any of sequences Thr His Gly Arg Gly Phe Ile (SEQ ID NO 1), Glu Gln Lys Tyr Ser Phe Leu (SEQ ID NO 2), Asp Gln Lys Tyr Ser Phe Leu (SEQ ID NO 3), Thr His Gly Arg (SEQ ID NO 4), Glu Gln Lys Tyr (SEQ ID NO 5), Asp Gln Lys Tyr (SEQ ID NO 6), His Gly Arg, Glu GlnLys, and Asp Gln Lys.

### Claim 7 (depends on 1, 6)

The oligopeptide according to claim 1 for use in the treatment or prevention of cancer, a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts which oligopeptide consists of or comprises a sequence having at least 70%, in particular at least 80%, similarity to any of the sequences defined in claim 6, wherein similarity to an oligopeptide means percentage of amino acids of the total number of amino acids of the oligopeptide replaced by conservative replacement.

### Claim 8 (depends on 1)

The oligopeptide according to claim 1, wherein the oligopeptide has a modification at one terminal end or modifications at both terminal ends of its sequence or a substitution of one, more or all of its amino acids having D-conformation by an amino acid or amino acids having L-conformation.

### Claim 9 (depends on 2)

The oligopeptide according to claim 2 for use in the treatment or prevention of cancer, a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts, wherein the oligopeptide has a modification at one terminal end or modifications at both terminal ends of its sequence or a substitution of one, more or all of its amino acids having D-conformation by an amino acid or amino acids having L-conformation.

### Claim 10 (depends on 8)

The oligopeptide according to claim 8, wherein the modification(s) is/are acetylation of an N-terminal end and/or amidation of a C-terminal end of the oligopeptide or a covalent binding between an N-terminal amino acid and a C-terminal amino acid of the oligopeptide resulting in a cyclization of the oligopeptide.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A recombinant protein comprising a sequence of an oligopeptide according to claim 1, wherein X4 is Lys for use in the treatment or prevention of a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts
or
wherein X4 is Arg for use in the treatment or prevention of cancer, a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts.

### Claim 13 (depends on 3)

A recombinant protein comprising a sequence of an oligopeptide according to claim 3 for use in the treatment or prevention of cancer, a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair,
glaucoma, psoriasis, chronic varicose ulcers or follicular cysts.

### Claim 14 (depends on 3)

A recombinant nucleic acid which nucleic acid consists of or comprises a sequence coding for an oligopeptide according to claim 3 or a sequence complementary to this sequence.

### Claim 15 (depends on 14)

The recombinant nucleic acid according to claim 14, wherein the nucleic acid is contained in an expression vector.

### Claim 16 (depends on 1, 12, 14)

A pharmaceutical composition comprising at least one oligopeptide according to claim 1 for the use according to the respective claim and/or at least on recombinant protein according to claim 12 the use according to the respective claim and/or at least one recombinant nucleic acid according to claim 14 for use in the treatment or prevention of cancer, a vasoproliferative retinopathy, diabetic retinopathy, rheumatoid arthritis, arteriosclerotic plaques formation, cornea neo-vascularization, macular degeneration, deficient wound repair, glaucoma, psoriasis, chronic varicose ulcers or follicular cysts.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16 comprising a pharmaceutically acceptable carrier.

### Claim 18 (depends on 1, 12, 13)

An antibody generated from the use of an oligopeptide according to claim 1 or the recombinant protein according to claim 12, wherein X4 is Lys, or according to claim 13.

### Claim 19 (depends on 18)

The antibody of claim 18, wherein the oligopeptide comprises or consists of sequence His Gly Arg, Glu Gln Lys, or sequence Asp Gln Lys and the recombinant protein comprises one of sequences Glu Gln Lys and Asp Gln Lys.

### Claim 20 (depends on 18)

The antibody of claim 18, wherein the antibodies are configured for use in a diagnostic method performed in vitro.

### Claim 21 (depends on 20)

The antibody of to claim 20, wherein the diagnostic method is configured for diagnosis of preeclampsia, peripartum cardiomyopathy, delayed fetus growth, a condition related to an abnormal blood pressure, a depressive disorder, an anxiety disorder, or an angiogenesis-dependent disease, wherein the angiogenesis-dependent disease is cancer, a vasoproliferative retinopathy, diabetic retinopathy or rheumatoid arthritis.
